|
WO2021068961A1
|
|
Inhalation solution pharmaceutical composition and preparation method therefor
|
|
WO2021047583A1
|
|
Tricyclic pyrazole derivative and preparation thereof
|
|
WO2021047581A1
|
|
Hexahydrobenzopyrazole derivative and preparation therefof
|
|
WO2021047470A1
|
|
Method for preparing peptide amide compound and intermediate thereof
|
|
WO2021043117A1
|
|
Impurity detection method for 2-((1s,2s,3r,6s,8s)-2-(aminomethyl)tricyclo[4.2.1.0 3,8]nonane-2-yl)acetate benzenesulfonate or composition thereof
|
|
WO2021032209A1
|
|
Anti-influenza virus compound, preparation method and use thereof
|
|
WO2021036975A1
|
|
Peptide amide composition and preparation method therefor
|
|
CN112279848A
|
|
Pan-JAKs inhibitor and application thereof
|
|
WO2021013085A1
|
|
Peptide amide salt, preparation method therefor and use thereof in medicine
|
|
WO2021013086A1
|
|
Deuterated peptide amide compound, and preparation method therefor and application thereof in medicine
|
|
WO2020239103A1
|
|
Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
|
|
CN112010858A
|
|
BTK inhibitor, preparation method and pharmaceutical application thereof
|
|
CN111995512A
|
|
All-racemic plant alcohol composition and preparation method and application thereof
|
|
CN111747942A
|
|
Spiro-containing derivative with beta 2 receptor agonistic activity and M receptor antagonistic activity and application thereof in medicine
|
|
CN111574529A
|
|
Muscarinic receptor M3 antagonists and β 2-adrenergic receptor agonist bridged ring derivatives
|
|
CN111517930A
|
|
Preparation method and intermediate of fused tricyclic derivative
|
|
WO2020155952A1
|
|
Preparation method for fused tricyclic derivative and intermediate
|
|
CN111517939A
|
|
Preparation method and intermediate of fused tricyclic derivative
|
|
WO2020155953A1
|
|
Fused tricyclic deuterated derivative, composition and use thereof
|
|
CN111517932A
|
|
Preparation method and intermediate of fused tricyclic derivative
|
